Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity

PURPOSE: Bevacizumab (Bev) is associated with improved progression-free survival in advanced epithelial ovarian cancer. The use of Bev in patients with gynecologic malignancy is increasing; however, little is known about cumulative toxicity and response in patients retreated with Bev. Our goal was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Laskey, Robin A, Richard, Scott D, Smith, Ashlee L, Lin, Jeff F, Beck, Tiffany L, Lesnock, Jamie L, Kelley, Joseph L, Olawaiye, Alexander B, Sukumvanich, Paniti, Krivak, Thomas C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968081/
https://www.ncbi.nlm.nih.gov/pubmed/24711703
http://dx.doi.org/10.2147/OTT.S57425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968081/
https://www.ncbi.nlm.nih.gov/pubmed/24711703
http://dx.doi.org/10.2147/OTT.S57425

Ejemplares similares